Remove Containment Remove Licensing Remove Production
article thumbnail

Codeine over the counter – 17 OTC products

Druggist

Without a doubt, codeine-containing products are one of the most commonly sold medicines in the UK. Most codeine products are combination products of codeine and another drug. Restrictions on the supply of codeine-containing products. Codeine over the counter: UK list of products. Codeine and aspirin.

article thumbnail

9 Calpol ALTERNATIVE products for children

Druggist

Today I will list Calpol alternative products, including other brands and forms of liquid paracetamol and alternative drugs. Although the intention is to find Calpol alternative products for toddlers and children, I included a few products, which have a minimum age restriction of 12 years and above. Calpol alternative products.

Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

article thumbnail

In the News: October Regulatory and Development Updates

Camargo

Unpacking the (Black) Box: Antares Licenses Urology Product with Boxed Warning. When the FDA requires a product’s labeling to include a boxed warning (also called a “black box warning” because the text is surrounded by black border), the potential market value of the drug often drops severely. In October, the U.S.

article thumbnail

Meningitis vaccine comes to the forefront with impressive study results

Pharmaceutical Technology

The response was more powerful than that generated by MenACWY-D – a licensed quadrivalent meningococcal vaccine marketed by GSK. NmCV-5 should be a cheaper option compared to existing quadrivalent vaccines, owing to more cost-effective production methods. percentage points (96% CI, −0.3 for serogroup W to 20.5 for serogroup A.

article thumbnail

CSL doses first patient with haemophilia B gene therapy Hemgenix

Pharmaceutical Technology

In the past year, Hemgenix has been granted approval by the US Food and Drug Administration (FDA) and has received conditional marketing authorisation from the European Commission (EC) and the UK’s Medicines and Healthcare products Regulatory Agency (MHRA). This followed positive results from CSL’s Phase III HOPE-B trial (NCT03569891).

article thumbnail

Syncromune and Eucure enter antibody licence deal

Pharmaceutical Technology

According to the deal, the worldwide rights for developing and marketing intratumoral combination treatment containing Eucure’s YH002 and two additional active ingredients of the Syncrovax therapy will be acquired by Syncromune.

Antibody 130
article thumbnail

Biologic Therapeutics Development, Part 2: Regulatory Pathways and Pharmacometric Analysis

Camargo

The development of biological products (or biologics) represents a major advancement in modern medicine, enabling the treatment of patients with many illnesses where no other therapeutics were previously available. The regulations regarding BLAs for therapeutic biological products are included in 21 CFR parts 600 , 601 , and 610.